Literature DB >> 17179401

Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study.

Marc C Heinrich1, Martin K Kuhlmann, Sonja Kohlbacher, Mario Scheer, Aleksandar Grgic, Martina B Heckmann, Michael Uder.   

Abstract

PURPOSE: To test in vitro whether gadolinium-based contrast agents induce fewer toxic effects on renal tubular cells than does an iodinated contrast medium at concentrations used for angiography.
MATERIALS AND METHODS: LLC-PK1 cells were incubated with iomeprol, gadopentetate dimeglumine, gadobenate dimeglumine, gadoterate meglumine, gadodiamide, and corresponding mannitol solutions for 24 hours at 37 degrees C in two experimental settings: measurements with equally attenuating solutions and measurements with equimolar solutions. Cytotoxicity was assessed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, trypan blue testing, and an assay to detect apoptosis and necrosis. Data were analyzed with analyses of variance and post hoc tests.
RESULTS: Yielding the same x-ray attenuation, iomeprol-300 and iomeprol-150 at concentrations of 2.34-18.75 mg of iodine per milliliter induced significantly (P < .001) lower inhibition of MTT conversion (74%-102% of undamaged control cells) compared with 15.63-125.00 mmol/L concentrations of the gadolinium-based agents (mean percentages of undamaged control cells: 48%-80%, 50%-87%, 60%-95%, and 56%-92% with gadopentetate dimeglumine, gadobenate dimeglumine, gadoterate meglumine, and gadodiamide, respectively). At equimolar concentrations (62.5 mmol/L), iomeprol-190 induced a mean extent of inhibition of MTT conversion (69% of undamaged control cells) similar to that induced by gadoterate meglumine (71%) and gadodiamide (70%), whereas gadopentetate dimeglumine and gadobenate dimeglumine induced stronger effects (63% and 64%, respectively; P < .001). At trypan blue testing, there were more dead cells after incubation with 125 mmol/L gadopentetate dimeglumine than after incubation with iomeprol-190 (57% vs 19%, P < .001). The 125 mmol/L gadopentetate and gadobenate formulations induced more necrosis and apoptosis than did gadoterate meglumine, gadodiamide, and iomeprol (mean percentage difference between treated and untreated control cells: for necrosis, +124%, +95%, +17%, -6%, and +3%, respectively; for apoptosis, +34%, +35%, +13%, +4%, and +5%, respectively; P < .001).
CONCLUSION: At angiographic concentrations, gadolinium-based contrast agents do not induce fewer cytotoxic effects on cultured renal tubular cells than does iomeprol. (c) RSNA, 2007.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17179401     DOI: 10.1148/radiol.2422060245

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

1.  The dogma that gadolinium contrast media are less nephrotoxic than iodine agents for X-ray angiography is a misconception.

Authors:  Ulf Nyman; Barbara Elmståhl; Mats Nilsson
Journal:  Heart Vessels       Date:  2007-05-21       Impact factor: 2.037

2.  MRI study of subconjunctival and intravitreal injections.

Authors:  S Kevin Li; Jinsong Hao; Hongshan Liu; Jing-huei Lee
Journal:  J Pharm Sci       Date:  2012-03-30       Impact factor: 3.534

3.  Iodine contrast iso-attenuating with diagnostic gadolinium doses in CTA and angiography results in ultra-low iodine doses. A way to avoid both CIN and NSF in azotemic patients?

Authors:  Ulf Nyman; Barbara Elmståhl; Håkan Geijer; Peter Leander; Torsten Almén; Mats Nilsson
Journal:  Eur Radiol       Date:  2010-08-29       Impact factor: 5.315

4.  Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.

Authors:  Peter J Wermuth; Francesco Del Galdo; Sergio A Jiménez
Journal:  Arthritis Rheum       Date:  2009-05

Review 5.  Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.

Authors:  Hale Ersoy; Frank J Rybicki
Journal:  J Magn Reson Imaging       Date:  2007-11       Impact factor: 4.813

6.  Linearity and shift invariance for quantitative magnetic particle imaging.

Authors:  Kuan Lu; Patrick W Goodwill; Emine U Saritas; Bo Zheng; Steven M Conolly
Journal:  IEEE Trans Med Imaging       Date:  2013-04-05       Impact factor: 10.048

7.  Assessment of Gadobutrol Safety in Combination with Ionizing Radiation Using a Preclinical MRI-Guided Radiotherapy Model.

Authors:  Michael S Petronek; Emily J Steinbach; Amanda L Kalen; Zachariah J Builta; Cameron M Callaghan; Dan E Hyer; Douglas R Spitz; Ryan T Flynn; John M Buatti; Vincent A Magnotta; Diana Zepeda-Orozco; Joël J St-Aubin; Bryan G Allen
Journal:  Radiat Res       Date:  2021-03-01       Impact factor: 2.841

Review 8.  Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.

Authors:  Moshe Rogosnitzky; Stacy Branch
Journal:  Biometals       Date:  2016-04-06       Impact factor: 2.949

9.  Serum Neutrophil Gelatinase-Associated Lipocalin and Urinary Kidney Injury Molecule-1 as Potential Biomarkers of Subclinical Nephrotoxicity After Gadolinium-Based and Iodinated-Based Contrast Media Exposure in Pediatric Patients with Normal Kidney Function.

Authors:  Brankica Spasojević-Dimitrijeva; Jelena Kotur-Stevuljević; Milan Đukić; Dušan Paripović; Gordana Miloševski-Lomić; Vesna Spasojević-Kalimanovska; Polina Pavićević; Jadranka Mitrović; Mirjana Kostić
Journal:  Med Sci Monit       Date:  2017-09-06

10.  Lack of nephrotoxicity of gadopentetate dimeglumine-enhanced non-vascular MRI and MRI without contrast agent in patients at high-risk for acute kidney injury.

Authors:  Ebru Gok Oguz; Ahmet Kiykim; Kenan Turgutalp; Refik Olmaz; Onur Ozhan; Necati Muslu; Mehmet Horoz; Simge Bardak; Mehmet Ali Sungur
Journal:  Med Sci Monit       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.